| Nome |
# |
|
EXPLORING THE AMYLOID BETA (ABETA) DEPENDENT METABOLIC
FINGERPRINT OF HIPPOCAMPAL NEURONS BY TWO-DIMENSIONAL COMPREHENSIVE GAS CHROMATOGRAPHY: POTENTIALS IN DRUG DISCOVERY STUDIES, file e27ce426-f62c-2581-e053-d805fe0acbaa
|
2773
|
|
Development of covalent NLRP3 inflammasome inhibitors: chemistry and biological activity, file e27ce42f-1c04-2581-e053-d805fe0acbaa
|
582
|
|
In vitro pharmacological evaluation of multitarget agents for thromboxane prostanoid receptor antagonism and COX-2 inhibition, file e27ce428-5e9e-2581-e053-d805fe0acbaa
|
557
|
|
NEW NON-COVALENT INHIBITORS OF NLRP3 INFLAMMASOME ATPASE ACTIVITY, file e27ce42f-32eb-2581-e053-d805fe0acbaa
|
445
|
|
Cardiac Epi-Metabolic Signature Revealed by Integrated Omics Approach in Diabetic Patients: Rescue by Active DNA Demethylation via TET-TDG Complex Reactivation, file e27ce42c-b04b-2581-e053-d805fe0acbaa
|
442
|
|
NO-Donor Dihydroartemisinin Derivatives as Multitarget Agents for the Treatment of Cerebral Malaria, file e27ce427-b4cc-2581-e053-d805fe0acbaa
|
370
|
|
Inhibition of NLRP3 ATPase activity: a new strategy to fight chronic inflammatory diseases, file e27ce42f-0b4e-2581-e053-d805fe0acbaa
|
253
|
|
Amodiaquine analogues containing NO-donor substructures: Synthesis and their preliminary evaluation as potential tools in the treatment of cerebral malaria, file e27ce426-bdc3-2581-e053-d805fe0acbaa
|
235
|
|
Carnosine analogues containing NO-donor substructures: Synthesis, physico-chemical characterization and preliminary pharmacological profile, file e27ce426-ead8-2581-e053-d805fe0acbaa
|
225
|
|
NO-Donor Phenols: A New Class of Products Endowed with Antioxidant and Vasodilator Properties, file e27ce426-aadd-2581-e053-d805fe0acbaa
|
224
|
|
Electrophilic Warhead-Based Design of Compounds Preventing
NLRP3 Inflammasome-Dependent Pyroptosis, file e27ce427-0bb3-2581-e053-d805fe0acbaa
|
207
|
|
Pharmacological inhibition of NLRP3 inflammasome attenuates myocardial ischemia/reperfusion injury by activation of RISK and mitochondrial pathways, file e27ce42b-3243-2581-e053-d805fe0acbaa
|
193
|
|
Is NLRP3 inflammasome a new pharmacological target in myocardial ischemia/reperfusion injury?, file e27ce428-be85-2581-e053-d805fe0acbaa
|
171
|
|
α-ketoglutarate dehydrogenase inhibition counteracts breast cancer-associated lung metastasis, file e27ce42c-cfbd-2581-e053-d805fe0acbaa
|
147
|
|
In silico study of NLRP3: towards selective inhibition with small molecules, file e27ce42f-1c08-2581-e053-d805fe0acbaa
|
136
|
|
Edaravone derivatives containing NO-donor functions, file e27ce426-bc77-2581-e053-d805fe0acbaa
|
130
|
|
A Comparative Study on the Efficacy of NLRP3 Inflammasome Signaling Inhibitors in a Pre-clinical Model of Bowel Inflammation, file e27ce42d-984c-2581-e053-d805fe0acbaa
|
115
|
|
A New Gateway for Rheumatoid Arthritis: COXIBs with an Improved Cardiovascular Profile, file e27ce427-548c-2581-e053-d805fe0acbaa
|
103
|
|
Synthesis, physico-chemical characterization, andbiological activities of new carnosine derivatives stablein human serum as potential neuroprotective agents, file e27ce426-c650-2581-e053-d805fe0acbaa
|
98
|
|
Stable Oxidative Cytosine Modifications Accumulate in Cardiac Mesenchymal Cells from Type2 Diabetes Patients: Rescue by alpha Ketoglutarate and TET-TDG Functional Reactivation, file e27ce42c-8ce9-2581-e053-d805fe0acbaa
|
96
|
|
Design, Synthesis, and Evaluation of Acrylamide Derivatives as Direct NLRP3 Inflammasome Inhibitors, file e27ce42b-688b-2581-e053-d805fe0acbaa
|
85
|
|
Synthesis of Small Molecules as Potential DNA Methylation Modulators, file e27ce428-513c-2581-e053-d805fe0acbaa
|
83
|
|
Do P2Y12 receptor antagonism and NLRP3 inhibition exert additive cardioprotective effects against ischemia/reperfusion injury?, file e27ce430-423e-2581-e053-d805fe0acbaa
|
79
|
|
Targeting of NLRP3 Inflammasome With a Novel Selective Inhibitor as a
Suitable Strategy for the Pharmacological Treatment of Bowel Inflammation, file e27ce42c-dbdf-2581-e053-d805fe0acbaa
|
74
|
|
In the search for new NLRP3 inhibitors: chemical modulation of the 1-(piperidin-4-yl)-1,3-dihydro-2 Hbenzo[d]imidazole-2-one scaffold, file 08889351-65f4-45f0-9414-657c773f233e
|
73
|
|
Ticagrelor Conditioning Effects Are Not Additive to Cardioprotection Induced by Direct NLRP3 Inflammasome Inhibition: Role of RISK, NLRP3, and Redox Cascades, file e27ce430-3d0d-2581-e053-d805fe0acbaa
|
68
|
|
Nonsteroidal anti-inflammatory drugs: Exploiting bivalent COXIB/TP antagonists for the control of cardiovascular risk, file e27ce42e-e6ca-2581-e053-d805fe0acbaa
|
67
|
|
Design and synthesis of encorafenib-based BRAF-V600E degraders, file d8e03593-a5c7-4f96-9d2b-d9bc3af47ed2
|
65
|
|
A rapid screening for cytochromes P450 catalysis on new chemical entities: cytochrome P450 BM3 and 1,2,5-oxadiazole derivatives, file e27ce427-b6d0-2581-e053-d805fe0acbaa
|
58
|
|
Chemical modulation of the 1-(Piperidin-4-yl)-1,3-dihydro-2h-benzo[d]imidazole-2-one scaffold as a novel NLRP3 inhibitor, file e27ce432-3ce7-2581-e053-d805fe0acbaa
|
57
|
|
A new series of amodiaquine analogues modified in the basic side chain with in vitro antileishmanial and antiplasmodial activity, file e27ce426-b440-2581-e053-d805fe0acbaa
|
55
|
|
Edaravone derivatives containing NO-donor functions, file e27ce426-bc79-2581-e053-d805fe0acbaa
|
50
|
|
Designing Multitarget Anti-inflammatory Agents: Chemical Modulation of the Lumiracoxib Structure toward Dual Thromboxane Antagonists-COX-2 Inhibitors., file e27ce427-b2ad-2581-e053-d805fe0acbaa
|
47
|
|
Design and synthesis of SWIR emitters for optical imaging, file a3c77925-a20a-4f10-b791-18737969052f
|
41
|
|
Breakthroughs in medicinal chemistry: New targets and mechanisms, new drugs, new hopes-7, file e27ce432-52fe-2581-e053-d805fe0acbaa
|
39
|
|
Design and synthesis of N-benzoyl amino acid derivatives as DNA methylation inhibitors, file e27ce42b-8f91-2581-e053-d805fe0acbaa
|
37
|
|
Novel R-roscovitine NO-donor hybrid compounds as potential
pro-resolution of inflammation agents, file e27ce426-df67-2581-e053-d805fe0acbaa
|
32
|
|
New tools for the development of direct NLRP3 inflammasome inhibitors, file e27ce42d-016a-2581-e053-d805fe0acbaa
|
32
|
|
Multitarget antioxidant NO-donor organic nitrates: a novel ap-proach to overcome nitrates tolerance, an ex vivo study, file e27ce434-a776-2581-e053-d805fe0acbaa
|
32
|
|
Design, Synthesis and Pharmacological Evaluation of Anti-Pyroptotic Compounds Acting on NLRP3 Inflammasome Signaling Pathway: a New Start for Anti-Inflammatory Drugs?, file e27ce427-1b40-2581-e053-d805fe0acbaa
|
31
|
|
Targeting NLRP3 inflammasome: development of new covalent and non-covalent inhibitors of ATPase activity, file e27ce42e-c9c8-2581-e053-d805fe0acbaa
|
30
|
|
Inflammasome Inhibitors, file e27ce434-47a9-2581-e053-d805fe0acbaa
|
30
|
|
Ticagrelor Conditioning Effects Are Not Additive to Cardioprotection Induced by Direct NLRP3 Inflammasome Inhibition: Role of RISK, NLRP3, and Redox Cascades, file e27ce430-279f-2581-e053-d805fe0acbaa
|
28
|
|
Editorial: Neurological, Metabolic and Inflammatory Disorders: A Common Root in Inflammasome, file e27ce434-47b6-2581-e053-d805fe0acbaa
|
25
|
|
Development of an Acrylate Derivative Targeting the NLRP3 Inflammasome for the Treatment of Inflammatory Bowel Disease, file e27ce42b-95d4-2581-e053-d805fe0acbaa
|
23
|
|
Synthesis and preliminary evaluation of model compounds targeting the NLRP3 inflammasome pathways, file e27ce427-0659-2581-e053-d805fe0acbaa
|
21
|
|
Pharmacological characterization of new NLRP3 inflammasome inhibitors., file e27ce430-5aa6-2581-e053-d805fe0acbaa
|
14
|
|
EVALUATION OF THE ANTIPYROPTOTIC ACTIVITY OF NEW INFLAMMASOME INHIBITORS, file e27ce434-886b-2581-e053-d805fe0acbaa
|
14
|
|
Targeting NLRP3 inflammasome regulatory mechanisms: design of anti-pyroptotic compounds for autoinflammatory diseases, file e27ce427-065a-2581-e053-d805fe0acbaa
|
5
|
|
Stable Oxidative Cytosine Modifications Accumulate in Cardiac Mesenchymal Cells from Type2 Diabetes Patients: Rescue by alpha Ketoglutarate and TET-TDG Functional Reactivation, file e27ce42c-abc8-2581-e053-d805fe0acbaa
|
5
|
|
Investigation into the Use of Encorafenib to Develop Potential PROTACs Directed against BRAFV600E Protein, file d8cded6f-e57e-4e8c-87da-877e19c5510e
|
4
|
|
Electrophilic Warhead-Based Design of Compounds Preventing
NLRP3 Inflammasome-Dependent Pyroptosis, file e27ce427-0bb4-2581-e053-d805fe0acbaa
|
4
|
|
Carnosine analogues containing NO-donor substructures: Synthesis, physico-chemical characterization and preliminary pharmacological profile, file e27ce426-ead9-2581-e053-d805fe0acbaa
|
3
|
|
Do P2Y12 receptor antagonism and NLRP3 inhibition exert additive cardioprotective effects against ischemia/reperfusion injury?, file cafe8efa-2599-48b6-80d5-0c27d508951f
|
2
|
|
Structure-Antioxidant Activity Relationships in a Series of NO-Donor Phenols, file e27ce426-b041-2581-e053-d805fe0acbaa
|
2
|
|
Amodiaquine analogues containing NO-donor substructures: Synthesis and their preliminary evaluation as potential tools in the treatment of cerebral malaria, file e27ce426-bdc4-2581-e053-d805fe0acbaa
|
2
|
|
Synthesis, physico-chemical characterization, andbiological activities of new carnosine derivatives stablein human serum as potential neuroprotective agents, file e27ce426-c64f-2581-e053-d805fe0acbaa
|
2
|
|
Novel R-roscovitine NO-donor hybrid compounds as potential
pro-resolution of inflammation agents, file e27ce426-df66-2581-e053-d805fe0acbaa
|
2
|
|
Use of the Morita-Baylis-Hillman reaction in the design of compounds inhibiting NLRP3 inflammasome signaling pathways, file e27ce427-00af-2581-e053-d805fe0acbaa
|
2
|
|
Designing Multitarget Anti-inflammatory Agents: Chemical Modulation of the Lumiracoxib Structure toward Dual Thromboxane Antagonists-COX-2 Inhibitors., file e27ce427-bb7a-2581-e053-d805fe0acbaa
|
2
|
|
In vitro pharmacological evaluation of multitarget agents for thromboxane prostanoid receptor antagonism and COX-2 inhibition, file e27ce428-58dd-2581-e053-d805fe0acbaa
|
2
|
|
Nonsteroidal anti-inflammatory drugs: Exploiting bivalent COXIB/TP antagonists for the control of cardiovascular risk, file e27ce42c-810d-2581-e053-d805fe0acbaa
|
2
|
|
Nonsteroidal anti-inflammatory drugs: Exploiting bivalent COXIB/TP antagonists for the control of cardiovascular risk, file e27ce42c-810e-2581-e053-d805fe0acbaa
|
2
|
|
NO-Donor Dihydroartemisinin Derivatives as Multitarget Agents for the Treatment of Cerebral Malaria, file e27ce433-5823-2581-e053-d805fe0acbaa
|
2
|
|
A new series of amodiaquine analogues modified in the basic side chain with in vitro antileishmanial and antiplasmodial activity, file e27ce426-b43f-2581-e053-d805fe0acbaa
|
1
|
|
Amphiphilic NO-Donor Antioxidants, file e27ce426-b66a-2581-e053-d805fe0acbaa
|
1
|
|
Edaravone derivatives containing NO-donor functions, file e27ce426-bc76-2581-e053-d805fe0acbaa
|
1
|
|
A rapid screening for cytochromes P450 catalysis on new chemical entities: cytochrome P450 BM3 and 1,2,5-oxadiazole derivatives, file e27ce427-c541-2581-e053-d805fe0acbaa
|
1
|
|
Design and synthesis of N-benzoyl amino acid derivatives as DNA methylation inhibitors, file e27ce42a-87e8-2581-e053-d805fe0acbaa
|
1
|
|
NO-Donor Dihydroartemisinin Derivatives as Multitarget Agents for the Treatment of Cerebral Malaria, file e27ce42a-8cbe-2581-e053-d805fe0acbaa
|
1
|
|
Design, Synthesis, and Evaluation of Acrylamide Derivatives as Direct NLRP3 Inflammasome Inhibitors, file e27ce42a-a55c-2581-e053-d805fe0acbaa
|
1
|
| Totale |
8842 |